Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) has been assigned a consensus rating of “Hold” from the eight analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.67.
A number of brokerages have recently commented on AFIB. Canaccord Genuity Group cut their price objective on shares of Acutus Medical from $10.00 to $3.00 and set a “hold” rating for the company in a research report on Friday, January 14th. William Blair reaffirmed a “market perform” rating on shares of Acutus Medical in a research report on Thursday, March 31st. BTIG Research raised shares of Acutus Medical from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 27th. Zacks Investment Research lowered shares of Acutus Medical from a “hold” rating to a “sell” rating in a research report on Monday, April 4th. Finally, UBS Group lowered shares of Acutus Medical from a “buy” rating to a “hold” rating in a research report on Friday, January 14th.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new stake in shares of Acutus Medical during the third quarter worth approximately $1,625,000. BlackRock Inc. increased its holdings in shares of Acutus Medical by 18.7% during the third quarter. BlackRock Inc. now owns 1,271,601 shares of the company’s stock worth $11,241,000 after buying an additional 200,749 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its holdings in shares of Acutus Medical by 39.5% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 53,000 shares of the company’s stock worth $181,000 after buying an additional 15,000 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Acutus Medical during the third quarter worth approximately $225,000. Finally, Trexquant Investment LP bought a new stake in shares of Acutus Medical during the third quarter valued at approximately $219,000. 62.97% of the stock is owned by institutional investors.
Acutus Medical (NASDAQ:AFIB – Get Rating) last announced its quarterly earnings data on Wednesday, March 30th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.21). The company had revenue of $4.36 million for the quarter, compared to analyst estimates of $4.30 million. Acutus Medical had a negative net margin of 681.71% and a negative return on equity of 116.28%. As a group, equities analysts forecast that Acutus Medical will post -3.17 earnings per share for the current year.
Acutus Medical Company Profile (Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
- Intuitive Surgical is an Intuitive Buy
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.